Objective: Postnatal HIV-1 mother-to-child transmission (MTCT) occurs in spite of antiretroviral therapy. Co-infections in breast milk with cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are associated with increased HIV-1 shedding in this compartment. We investigated CMV levels and EBV detection in breast milk as potential risk factors for MTCT of HIV-1 via breastfeeding.
Introduction
In the absence of antiretroviral prophylaxis, breastfeeding accounts for up to half of mother-to-child transmission (MTCT) of HIV-1 [1] . An estimated 260 000 children acquired HIV infection in 2012, of whom more than 90% were living in sub-Saharan Africa [2] . However, breast milk provides essential nutrition and immunological protection against mucosal pathogens, and breastfeeding remains crucial for infant survival in resource-limited settings [3, 4] .
Apart from HIV-1, breast milk is also a vehicle for the transmission to the infant of other viruses infecting leukocytes, such as cytomegalovirus (CMV) and human T-cell lymphoma/leukemia virus (HTLV-1) [5] [6] [7] . Epstein-Barr virus (EBV), although frequently shed in breast milk, is not significantly transmitted from mother to child via this route [8, 9] . MTCT of HIV-1 via breastfeeding has been associated with levels of cell-free and cell-associated virus in breast milk [10] , plasma HIV-1 RNA and maternal CD4 þ levels [11, 12] , duration and pattern of breastfeeding [13, 14] , and subclinical [15] or symptomatic mastitis [16] . However, since the vast majority of breastfed infants of HIV-1-infected mothers escape infection even without maternal or infant prophylaxis, other factors must drive HIV-1 transmission by breastfeeding [17] . Co-infection with CMV and EBV may be associated with increased risk of HIV-1 transmission through mechanisms enhancing reciprocal viral replication, as has been shown for herpes simplex virus type 2 [18] .
Cytomegalovirus is commonly excreted in breast milk with rates of detection estimated to be 88-99% in two studies on mothers with preterm infants [19, 20] . Breast milk is a main source of MTCTof CMVand is estimated to occur in 40-66% of breast-fed infants in early life [21, 22] . In HIV-1-infected mothers, breast milk CMV level and maternal CD4 þ cell count have been shown to be independently associated with early infant CMV acquisition [23] . In a cross-sectional study of HIV-1 -infected breastfeeding women in Zimbabwe, breast milk CMVand EBV levels were independently associated with detection of breast milk HIV-1 RNA after adjustment for indicators of mastitis and plasma HIV-1 RNA concentration [24] .
Systemic CMV reactivation may be accompanied by CMV antigenemia/viruria; however, local CMV reactivation (intra-mammary, colon, lung, genital) is usually asymptomatic and without simultaneous detection of markers of systemic infection measured in peripheral blood or urine [25] . In-vitro studies have shown that interactions between HIV-1 and CMV may be bidirectional, with CMV and HIV-1 enhancing each other's replication [26] . Indirect interactions may involve CMVmediated T-cell activation, facilitating HIV-1 replication, and coexist with direct facilitating mechanisms involving CMV proteins such as chemokine receptor homologue (US28) acting as a co-factor for HIV-1 cell entry [27] .
Epstein-Barr virus shedding in breast milk has similarly been described, but less so than for CMV, with detection rates of around 45% [8, 24] . In addition, breast milk does not appear to be a significant source of MTCT of EBV [9] . In-vitro studies have demonstrated that EBV enhances replication of HIV-1 in CD4 þ lymphocytes [28] , and that EBV and HIV-1 co-infection of T cells increases HIV-1 production by transactivation of the HIV-1 long terminal repeats by Epstein-Barr nuclear antigen 2 [29] . An increase of cell-associated EBV DNA levels in blood is observed in HIV-viremic patients compared to HIV-nonviremic and healthy controls [30] .
To optimize the management of HIV-1-infected mothers, it is important to understand the pathogenesis of MTCT of HIV-1, and identify factors associated with postnatal MTCT of HIV-1. Here, we report the findings of a case-control study that investigated breast milk CMV levels and breast milk EBV detection as factors associated with MTCT of HIV-1 via breastfeeding.
Materials and methods

Study design
The case-control study was nested in a large infant feeding intervention cohort among both HIV-infected and HIVuninfected mothers in KwaZulu-Natal, South Africathe Vertical Transmission Study (VTS), with enrollment between August 2001 and September 2004. Rates of MTCT of HIV-1 via breastfeeding and detailed description of the study design and methods are published [14, 31] . Study participants were antiretroviral therapy (ART)-naive except for single-dose nevirapine (sdNVP) provided to all HIV-infected women and their newborns during delivery as per national guidelines at the time. Mothers and infants attended clinics for monthly followup and collection of an infant dried blood spot (DBS) sample by heel prick for HIV-1 molecular testing, and a breast milk sample (10 ml) from each breast of the mother. Breast milk samples were maintained at 48C and transported overnight to the Africa Centre Virology Laboratory in Durban, where it was stored as whole breast milk at À808C until further analysis. Infants were considered to have been infected postnatally if they had a negative HIV-1 RNA viral load result at 6 weeks of age and a positive result at any time thereafter. Maternal plasma viral load (Nuclisens EasyQ HIV-1 assay; Biomerieux, Boxtel, the Netherlands) and CD4 þ cell count (Epics XL; Beckman Coulter, California, USA) were obtained from samples taken at enrollment, 6 weeks or 26 weeks postdelivery. All women provided informed consent, and the VTS and breast milk analyses were approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal.
Study population
Cases were all mothers included in the VTS with established HIV-1 infection and proven postnatal transmission of HIV-1 to their infants via breastfeeding [14] . Sixty-two mothers with breast milk sample available for HIV-1 and CMV/EBV testing met the criteria of inclusion. The estimated timing of infant HIV-1 acquisition was taken as the midpoint between the last negative and the first positive HIV-1 RNA test result. The breast milk sample selected for testing was that obtained immediately prior to the estimated timing of infant HIV-1 acquisition. Controls were 62 HIV-positive mothers with HIV-uninfected infants matched for infant age at the time of breast milk sample collection in a 1 : 1 ratio and randomly selected when several samples were available at the same date. Timing of sampling in days following delivery in cases and controls were similar, with a nonstatistically significant median time difference between groups of AE4.0 days [interquartile range (IQR) À18 to 12) (P ¼ 0.4). The median time between last undetectable and first detectable HIV-1 RNA test in cases was 145 days (IQR 82-313).
Quantification of HIV-1 cell-free and cellassociated virus in breast milk
Cell-free HIV-1 RNA quantification in breast milk samples was performed as previously described [10, 13] . In brief, RNA was extracted from 500 ml breast milk lactoserum, including the lipid fraction, to maximize detection of virus entrapped by lipids, using the magnetic particle-based Abbott Sample Preparation System (ASPS) assay (Abbott Laboratories, Wiesbaden, Germany). HIV-1 viral load was quantified using the Generic HIV Charge Virale assay (Biocentric, Bandol, France) on the MJ MiniOpticon quantitative PCR detection platform (BioRad, Hercules, California, USA); the lower limit of detection was 375 HIV-1 copies per ml.
DNA was extracted from cell pellet obtained from 1.5 ml of whole breast milk using the QIAamp DNA Mini Kit (Qiagen, Valencia, California, USA). Cell-associated HIV-1 DNA quantification was performed using the Generic HIV DNA Cell assay (Biocentric) as previously described [10] , with a sample input normalized through a human glyceraldehyde 3-phosphate dehydrogenase gene quantification assay to compensate for cell lysis [32] . HIV-1 DNA results were expressed as copies per 10 6 equivalent breast milk cells with a lower limit of detection of 560 HIV-1 DNA copies/10 6 breast milk cells.
Quantification of cytomegalovirus and Epstein-Barr virus DNA in breast milk
Cytomegalovirus and EBV DNA viral load quantification was performed on pooled left and right breast milk cell pellets. Although maternal CMV and EBV serostatus was not determined for individual breast milk samples, previous investigation into our study population using antenatal plasma samples yielded very high CMV (99.5%) and EBV (97%) prevalence rates (unpublished data). We used commercial quantitative PCR (qPCR) assays for CMV [PrimerDesign GeneSig qPCR Kit for Human Herpes Virus 5 (Cytomegalovirus), Southampton, UK] and EBV [PrimerDesign GeneSig qPCR Kit for Human Herpes Virus 4 (Epstein Barr), Southampton, UK] quantification. DNA extraction was performed using the QIAamp DNA Mini Kit (Qiagen), and qPCR was performed using the LightCycler 480 system (Roche, Basel, Switzerland). The input volume into the qPCR assays for both viruses were 5 ml of a 5-ng/ml product (manufacturer's instructions), with a total input of 25 ng DNA per reaction corresponding to an equivalent of 3.8 Â 10 4 breast milk cells. Results were expressed as copies CMVor EBV DNA per 10 6 breast milk cells, with a lower limit of detection of 528 DNA copies/10 6 breast milk cells.
Statistical analysis
Continuous data were assessed with Student's t test and Wilcoxon Mann-Whitney test when their distributions were normal or non-normal, respectively; categorical variables were assessed with chi-square or Fisher's exact test if the number was small.
The Wilcoxon signed-rank test for paired data with non-Gaussian distributions and the Student's t test for paired data with Gaussian distributions were used to compare breast milk viral loads of HIV-1 RNA and DNA, and for CMV and EBV DNA between cases and controls. The McNemar's test was used for comparison of EBV DNA levels between cases and controls. Statistical significance was set at a P value less than 0.05.
To estimate the adjusted risk of postnatal transmission associated with CMV and EBV, we built a conditional logistic regression model. Variables associated with postnatal transmission on the basis of a P value less than 0.20 in univariate analysis were included in the multivariable model, and we used a backward selection. All analyses were performed using SAS Enterprise Guide version 5.1 (SAS Institute, Cary, North Carolina, USA). We used the mean value obtained between left and right breasts for HIV-1 RNA and DNA as the final value in breast milk. All specimens with undetectable levels of breast milk CMVor EBV DNA, breast milk HIV-1 RNA and DNA, and plasma HIV-1 RNA were assigned a value equal to half the lower limit of detection.
Results
Study population characteristics
Maternal HIV-1 plasma viral load was significantly higher in cases than in controls, and there was a trend towards lower CD4 þ cell counts ( Table 1 ). The two groups were not significantly different regarding maternal age, socioeconomic and demographic characteristics, mode of delivery or duration of rupture of membranes, and infant characteristics at birth. There were no reports of clinical mastitis at sample collection in any mothers.
HIV-1 RNA and DNA in breast milk and association with HIV-1 transmission Breast milk HIV-1 RNA level was significantly higher in cases than in controls [median (IQR) 1405 (188-6606) and 188 (188-188) copies/ml, respectively; P < 0.001] (Fig. 1a ). HIV-1 RNA was more frequently detectable in the breast milk of cases [40/62 (64.5%)] than in that of controls [10/60 (16.7%; P < 0.001]. Since HIV-1 RNA was frequently undetectable from controls, the detection rate was used for further analysis. HIV-1 MTCT was significantly associated with breast milk HIV-1 RNA detection ( Table 2 ). Sufficient breast milk sample was available for HIV-1 DNA measurement in 29 of 62 of cases and 40 of 62 of controls, yielding 23 case-control pairs. HIV-1 DNA was detected significantly more frequently in cases (24/29, 82.8%) than in controls (10/40, 25%; P < 0.001). The median (IQR) breast milk HIV-1 DNA level was significantly higher in cases [5002 (1993-14890) ] than that in controls [280 (280-462) copies/10 6 breast milk cells; P < 0.001] (Fig. 1b ). CD4 þ cell count was marginally associated with MTCT of HIV-1 (P ¼ 0.068).
Detection and quantification of cytomegalovirus DNA and Epstein-Barr virus DNA in breast milk
Cytomegalovirus DNA was detectable in most breast milk samples of cases and controls (both 96.8%, 60 out of 62). Median (IQR) CMV DNA viral load was significantly higher in cases [88 044 (18 586-233 904)] than in controls [11 167 (3221-31 152 ) copies/10 6 breast milk cells; P < 0.001] (Fig. 1c ).
Epstein-Barr virus DNA was detectable in a higher proportion of breast milk samples of cases than controls [23/62 (37.1%) and 10/62 (16.1%), respectively; P ¼ 0.009]. Levels of EBV DNA were higher in cases than in controls (P ¼ 0.023) (Fig. 1d ). Since EBV DNA was frequently undetectable in controls, breast milk detection rate was used for further analysis. Feeding mode (exclusive and mixed breastfeeding) was not associated with significant differences in CMV viral load or EBV detection in breast milk.
Impact of cytomegalovirus DNA viral load and
Epstein-Barr virus DNA detection in breast milk and mother-to-child transmission of HIV-1 Cytomegalovirus viral load in breast milk was significantly associated with a 2.5-folds greater odds of postnatal HIV-1 MTCT. Increased CMV levels were associated 148 AIDS 2015, Vol 29 No 2 with increased HIV-1 RNA shedding in breast milk. In further analysis, HIV-1 MTCT remained independently associated with CMV level after adjustment for breast milk HIV-1 RNA detection and plasma HIV-1 RNA levels.
Univariately, EBV detection in breast milk was also associated with HIV-1 MTCT. However, in multivariable analysis, adjusting for breast milk HIV-1 RNA detection, EBV DNA detection was no longer significantly associated with postnatal transmission of HIV-1 ( Table 2) .
Association between cytomegalovirus and Epstein-Barr virus DNA in breast milk with HIV-1 replication and CD4 R depletion
Breast milk CMV levels correlated positively with breast milk HIV-1 RNA in cases and controls ( Fig. 2a and b ).
A strong correlation was observed between CMV and HIV-1 DNA levels in breast milk for cases, but not for controls ( Fig. 2c and d) . Breast milk CMV levels correlated positively with plasma HIV-1 RNA levels in cases and controls ( Fig. 3a and b) . A significant inverse correlation was observed between breast milk CMV level and maternal CD4 þ cell count for cases, but not for controls ( Fig. 3c and d ).
No clear association was observed between EBV and HIV-1 RNA and DNA shedding in breast milk. Similarly, there was no association found between EBV DNA shedding in breast milk and CD4 þ cell count (data not shown).
Discussion
We show that CMV viral load in breast milk was significantly associated with MTCT of HIV-1 via breastfeeding, independently of HIV-1 RNA shedding in this compartment. EBV detection in breast milk may also be associated with MTCT of HIV-1, but only marginally so. This is the first study to demonstrate an independent association between CMV DNA in breast milk and postnatal MTCT of HIV-1. Similar to previous studies, CMV DNA was detectable in the majority of breast milk samples studied from this population of untreated HIV-1-infected mothers, with measured CMV levels significantly higher in breast milk than levels previously reported in blood. Recently, Gianella et al. [33] reported median (IQR) values of 1.73 (0.12-4.54) log 10 CMV DNA copies/10 6 peripheral blood mononuclear cells, compared to median (IQR) values of 4.4 (3.8-5.2) log 10 CMV DNA copies/10 6 breast milk cells, and Slyker et al. [23] described median (IQR) values of 1.8 (1.8-2.0) log 10 CMV copies/ml in plasma compared to 5.5 (5.0-6.4) log 10 CMV copies/ml in breast milk. In contrast to HIV-1, which we previously found to be 1-2 log 10 lower in breast milk compared to blood [13] , CMV DNA level appears to be significantly higher in BM than blood, suggesting efficient compartmentalized CMV replication in the mammary gland. CMV DNA may be cellassociated in a variety of infected breast milk cells, including mammary epithelial cells, monocytes and T cells that traffic into breast milk [4, 34] .
Epstein-Barr virus is less frequently detected in breast milk [24] . EBV-memory B cells are the reservoir of EBV. The proportion of B cells in breast milk is lower than that in the blood; B-cell count is also much lower than T-cell count in breast milk. This could explain in part why breast milk levels of EBV DNA were found to be lower than that of CMV DNA levels.
HIV-1 DNA and RNA levels in breast milk appeared strongly predictive of postnatal HIV-1 MTCT. We further observed a greater than two-folds greater odds of HIV-1 MTCT with every 1 log 10 increase in breast milk CMV DNA, independently of breast milk HIV-1 RNA level. It has been shown that a short-course prophylaxis of HIV-1 MTCT using NVP strongly impact on plasma and breast milk HIV-1 viral load 1 week after delivery with rebound levels peaking at 4 weeks, significant for plasma but not in breast milk, to prior levels [35] . Hence, at the time of breast milk sample collection, NVP traces were most likely to have disappeared with replication levels in breast milk rebounding to levels comparable to pre-entry in this study.
HIV-1 DNA, reflecting cell-associated HIV-1, was not included in the MTCT model since this parameter was only available for some breast milk samples. However, a strong association was observed for cases when CMV DNA was compared to HIV-1 DNA. High CMV and HIV-1 DNA levels in breast milk may be associated with an influx of leukocytes due to local or systemic inflammatory processes [36] , and consequently of both CMV and HIV-1-infected cells in breast milk. A second link between the two viruses may involve immune activation since high levels of CMV shedding in breast milk may target T-cell activation and facilitate reactivation of CD4 þ cells latently infected by HIV-1 and located in the mammary gland. Thus, CMV shedding in breast milk may be one factor driving the high level of immune activation observed in breast milk cells [37] , coupled with the high capacity of breast milk HIV-1-infected CD4 þ cells to produce HIV particles [38] . Impairment of the immune response against CMV may be a third mechanism involved in the poor control of both CMV and HIV-1 shedding in the mammary compartment. Hence, our data have shown that CMV DNA level in breast milk was associated with CD4 þ depletion in cases. We did not observe the same association in the control group, which may suggest that T-cell responses were somewhat more preserved in nontransmitters. Consistent with this observation, MTCT of CMV was recently shown to be strongly associated with levels of CMV DNA in breast milk and CD4 þ depletion in HIV-infected women [23] . Similarly, a decrease in T-cell population due to HIV-1 infection has been associated with the loss of control of herpes simplex type 2 replication in the female genital compartment [39] . These data imply that an impairment in T-cell response leads to herpes virus reactivation with compartmentalized HIV-1 replication. Thus, a specific anti-CMV default in T-cell response may facilitate intra-mammary CMV replication, which, in turn, may lead to an increase in HIV-1 replication and shedding in breast milk.
The study had several limitations. Firstly, due to the observational character, it is difficult to infer causality of the reported associations as CMV and EBV viral load might be a consequence of increased immunosuppression in transmitters. Secondly, since CMV and EBV shedding is mostly intermittent, interventional clinical trials are needed to describe longitudinal patterns of intermittent versus continuous shedding, and its effect on MTCT of HIV-1. Thirdly, we did not investigate the potential confounding influence in cases with high breast milk CMV shedding associated with the different immune milieu as found in subclinical mastitis.
The age of the infant was chosen as the only matching criterion for controls because age is associated with dramatic changes in breast milk composition over time.
Since breast milk HIV-1 viral load and CD4 þ T-cell count were important risk factors for HIV-1 transmission, we preferred not to use them as matching criteria. Further studies on breast milk in women on ART, using alternative ratios for case-control numbers, and matching criteria are needed to confirm the findings of this study.
The demonstrated association between CMV and EBV DNA and HIV-1 levels in this study may explain persistent shedding of HIV-1 in breast milk. Cellassociated levels of HIV-1 RNA and proviral DNA in breast milk have been shown to be refractory to treatment with ART [38] . We hypothesize that compartmentalized CMV and EBV replication may contribute to residual HIV-1 MTCT via breastfeeding for women receiving ART, as previously described [40] .
Targeting CMV and perhaps EBV replication in the mammary gland may be of interest as an adjuvant to ART prophylaxis of HIV-1 MTCT, and may have the additional effect of reducing CMV burden overall. Recent data, as to the longer-term sequelae of early infant CMV infection, have been published [41] . In addition, maternal plasma CMV DNA viral load has also been associated with increased mortality in HIV-1-infected women and their infants following 2 years after delivery [42] .
The study provides the first evidence of an independent association between CMV in breast milk, and postnatal MTCTof HIV-1. Further studies are needed to clarify the relationship between CMVand residual HIV-1 shedding in breast milk of mothers receiving antiretroviral prophylaxis.
